CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Major trials in coronary intervention from 2018 A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia Temporal trends in percutaneous coronary interventions thru the drug eluting stent era: Insights from 18,641 procedures performed over 12-year period Update in the Percutaneous Management of Coronary Chronic Total Occlusions Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 SCAI Expert Consensus Statement Update on Best Practices for Transradial Angiography and Intervention Quantitative angiography methods for bifurcation lesions: a consensus statement update from the European Bifurcation Club Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

Review Article2017 Feb 7;69(5):556-569.

JOURNAL:J Am Coll Cardiol. Article Link

Mode of Death in Heart Failure With Preserved Ejection Fraction

Vaduganathan M, Patel RB, Butler J et al. Keywords: epidemiology; mortality; outcomes

ABSTRACT


Little is known about specific modes of death in patients with heart failure with preserved ejection fraction(HFpEF). Herein, the authors critically appraise the current state of data and offer potential future directions. They conducted a systematic review of 1,608 published HFpEF papers from January 1, 1985, to December 31, 2015, which yielded 8 randomized clinical trials and 24 epidemiological studies with mode-of-death data. Noncardiovascular modes of death represent an important competing risk in HFpEF. Although sudden death accounted for ∼25% to 30% of deaths in trials, its definition is nonspecific; it is unclear what proportion represents arrhythmic deaths. Moving forward, reporting and definitions of modes of death must be standardized and tailored to the HFpEF population. Broad-scale systematic autopsies and long-term rhythm monitoring may clarify the underlying pathology and mechanisms driving mortal events. There is an unmet need for a longitudinal multicenter, global registry of patients with HFpEF to map its natural history.